Ann Pharmacother October 2021 PMID 33533262

Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne.

Julie Kalabalik-Hoganson, Kathleen M Frey, Ayse Elif Ozdener-Poyraz, Malgorzata Slugocki

Download social card

Mentions

Peak: 1 in Feb 2021

across 2 sources since Feb 2021

Extended reach

66,366

potential audience

Total likes

1,286

Video views

65,813

Mentions per month

Feb 2021 – Dec 2023

Where it's discussed

YouTube2 videos
X / Twitter1 posts

AI synopsis

What people are saying

Discussions highlight enthusiasm and recognition of the article's relevance, with comments such as 'Read Kalabalik-Hoganson's latest article' and references to its publication in a reputable journal, demonstrating high engagement and interest. The tone is respectful and optimistic, emphasizing the potential of Clascoterone as a new treatment option, which explains the generally positive agreement and moderate perceived impact.

AgreementModerate agreement

Most discussions acknowledge the article's importance and seem to agree on its potential benefits, as indicated by phrases like 'latest article' and recognition in reputable sources.

InterestHigh interest

The high interest score reflects curiosity and positive perceptions, with users expressing eagerness to read and discuss the publication.

EngagementHigh engagement

Posts show active engagement through references to the article title, enthusiasm for its content, and potential clinical implications, demonstrating a deeper interest rather than superficial reactions.

ImpactModerate impact

While some users recognize the publication's significance, especially for dermatology and acne treatment, the impact score remains moderate as discussions focus on interest and agreement rather than broad societal implications.

Abstract in brief

Clascoterone is a new topical cream that targets androgen receptors to treat acne and has shown promising efficacy and safety in clinical studies for patients aged 12 and older.
It works locally on the skin without systemic side effects, making it a good option especially for people who can't use or shouldn't use systemic treatments, such as pregnant women or males.
Long-term studies indicate that clascoterone is safe for up to 9 months, with mild skin reactions like erythema being the most common side effect.

Read the full abstract

All mentions

Effective Topical Anti-Androgens for Hair Loss Prevention

This video explores topical anti-androgens like Pyrilutamide, RU58841, and Breezula, discussing their potential to inhibit hair loss by blocking androgen receptors. It highlights recent research and developments in…

Haircafe · Dec 22, 2022 48,276 views

Breezula and Clascoterone: New Advances in Hair Loss Treatment

Breezula, a promising hair loss therapy, is being compared with pyrilutamide and clascoterone — a topical androgen receptor blocker approved for acne, now studied for hair loss. This video explores their potential in…

Haircafe · Dec 4, 2023 17,537 views

Annals of Pharmacotherapy Journal

@AnnalsofPharm · X

Read Kalabalik-Hoganson's latest article on Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne in Annals of Pharmacotherapy today! https://t.co/eu4xmgNJ5V

Feb 3, 2021 · 554 followers View post →